ASH 2022 Abstracts

AbstractWeb LinkLead AuthorSenior AuthorMER DataLEO Data
953 FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphomahttps://ash.confex.com/ash/2022/webprogram/Paper157194.htmlMaurerCerhanyesyes
2860 Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)https://ash.confex.com/ash/2022/webprogram/Paper160351.htmlWrightRimszayesno
724 Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCLhttps://ash.confex.com/ash/2022/webprogram/Paper159620.htmlWenzlNovakyesno
1541 Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphomahttps://ash.confex.com/ash/2022/webprogram/Paper170228.htmlStokesGandhiyesno
2957 Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortiumhttps://ash.confex.com/ash/2022/webprogram/Paper157083.htmlDayLink?yesyes
2889 Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphomahttps://ash.confex.com/ash/2022/webprogram/Paper167633.htmlTawfiqYucaiCReWEno
2900 Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Settinghttps://ash.confex.com/ash/2022/webprogram/Paper165419.htmlGileYucaiCReWEno
1591 Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Studyhttps://ash.confex.com/ash/2022/webprogram/Paper164988.htmlRuanFeldmanyesyes
4156 Molecular Landscape of Primary Refractory DLBCLhttps://ash.confex.com/ash/2022/webprogram/Paper156497.htmlBockNovakyesno
545 A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Studyhttps://ash.confex.com/ash/2022/webprogram/Paper167466.htmlHerveCerhanyesno
2966 Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Studyhttps://ash.confex.com/ash/2022/webprogram/Paper169575.htmlKhuranaMaureryesno
850 Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysishttps://ash.confex.com/ash/2022/webprogram/Paper169433.htmlKhuranaNowakowskinoyes
4207 Predictive Value of Staging PET/CT to Detect Bone Marrow Involvement in Marginal Zone Lymphoma (MZL): An Analysis from LEO MZL Working Grouphttps://ash.confex.com/ash/2022/webprogram/Paper162688.htmlAlduruccioLossosnoyes
798 Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Erahttps://ash.confex.com/ash/2022/webprogram/Paper165207.htmlDesaiCerhanyesno
793 Development of a Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphomahttps://ash.confex.com/ash/2022/webprogram/Paper164692.htmlLuanMartinyesyes
313 Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortiumhttps://ash.confex.com/ash/2022/webprogram/Paper164720.htmlRoddayParsons?yesno
Hypomagnesemia in Untreated Diffuse Large B-cell Lymphomahttps://ash.confex.com/ash/2022/webprogram/Paper171891.htmlGileWitzigyesno